Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB26FE0TS
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $57,211
Award facts
- Contract value 100% obligated
- $57,211.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $57,211.18 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens with an ultimate completion date of October 20, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor that serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026.
The Dupixent delivery represents a single transaction under AmerisourceBergen's comprehensive pharmaceutical prime vendor agreement, which enables the company to supply a broad range of medications and medical supplies to support military healthcare programs globally. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and other conditions, reflecting the company's role in providing specialty pharmaceutical products to the Defense Health Agency and affiliated government healthcare systems. AmerisourceBergen's demonstrated capacity to fulfill diverse federal medical procurement requirements through open competition, combined with its extensive pharmaceutical distribution network, positions the company as a key supplier within the Defense Logistics Agency's medical supply chain.
Quick answers
Who was awarded contract SPE2DB26FE0TS?
SPE2DB26FE0TS was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 17, 2025.
How much is contract SPE2DB26FE0TS worth?
The government has obligated $57,211 on SPE2DB26FE0TS.
Is contract SPE2DB26FE0TS an order under another contract?
Yes. SPE2DB26FE0TS is a delivery order under SPE2DB20D1100, an indefinite delivery contract.
Was contract SPE2DB26FE0TS competed?
The extent of competition for SPE2DB26FE0TS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award